Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery

Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery

Andrej Kidess, Adonis El Salloukh, Poonam Dutt, Pearse A Keane, Marie D Tsaloumas, Alastair K DennistonQueen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKIt is with great interest that we read the publication entitled "Critical appraisa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kidess A, El Salloukh A, Dutt P, Keane PA, Tsaloumas MD, Denniston AK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/9d19d9365766444e991a96d5029225b2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9d19d9365766444e991a96d5029225b2
record_format dspace
spelling oai:doaj.org-article:9d19d9365766444e991a96d5029225b22021-12-02T01:26:32ZMeasurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery1177-5483https://doaj.org/article/9d19d9365766444e991a96d5029225b22013-12-01T00:00:00Zhttp://www.dovepress.com/measurement-bias-between-optical-coherence-tomography-instruments-can--a15267https://doaj.org/toc/1177-5483 Andrej Kidess, Adonis El Salloukh, Poonam Dutt, Pearse A Keane, Marie D Tsaloumas, Alastair K DennistonQueen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKIt is with great interest that we read the publication entitled "Critical appraisal of ranibizumab in the treatment of diabetic macular edema" by Stewart.1 The author emphasized the importance of the vascular endothelial growth factor (VEGF) in the pathophysiology of diabetic macular edema (DME). As highlighted in that article, the anti-VEGF ranibizumab is a superior treatment compared to traditional argon photocoagulation, leading to better anatomical and functional results.In April 2013, the National Institute for Health and Care Excellence (NICE) of the UK approved the use of ranibizumab as a treatment option to treat diabetic macular edema of the eye if it has a central macular thickness (CMT) of 400 μm or more at the beginning of the treatment.2 The guidelines did not specify which optical coherence tomography (OCT) device(s) should be used for this assessment. This is important as, although good consistency has been shown in using the same instrument, there is a known divergence in CMT measurements between different instruments.3–6 For example, the Spectralis® OCT (Heidelberg Engineering; Carsbad, CA, USA) generally shows higher values of mean CMT in a normal eye compared to most other instruments, in part due to the retinal segmentation algorithm that it employs.4 We hypothesized that similar (or increased) differences might be observed in DME, and that for those countries (such as the UK) where a fixed CMT is used to define eligibility for treatment, the "lottery" of OCT instruments may influence eligibility.View original paper by Stewart.Kidess AEl Salloukh ADutt PKeane PATsaloumas MDDenniston AKDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 2299-2302 (2013)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Kidess A
El Salloukh A
Dutt P
Keane PA
Tsaloumas MD
Denniston AK
Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
description Andrej Kidess, Adonis El Salloukh, Poonam Dutt, Pearse A Keane, Marie D Tsaloumas, Alastair K DennistonQueen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKIt is with great interest that we read the publication entitled "Critical appraisal of ranibizumab in the treatment of diabetic macular edema" by Stewart.1 The author emphasized the importance of the vascular endothelial growth factor (VEGF) in the pathophysiology of diabetic macular edema (DME). As highlighted in that article, the anti-VEGF ranibizumab is a superior treatment compared to traditional argon photocoagulation, leading to better anatomical and functional results.In April 2013, the National Institute for Health and Care Excellence (NICE) of the UK approved the use of ranibizumab as a treatment option to treat diabetic macular edema of the eye if it has a central macular thickness (CMT) of 400 μm or more at the beginning of the treatment.2 The guidelines did not specify which optical coherence tomography (OCT) device(s) should be used for this assessment. This is important as, although good consistency has been shown in using the same instrument, there is a known divergence in CMT measurements between different instruments.3–6 For example, the Spectralis® OCT (Heidelberg Engineering; Carsbad, CA, USA) generally shows higher values of mean CMT in a normal eye compared to most other instruments, in part due to the retinal segmentation algorithm that it employs.4 We hypothesized that similar (or increased) differences might be observed in DME, and that for those countries (such as the UK) where a fixed CMT is used to define eligibility for treatment, the "lottery" of OCT instruments may influence eligibility.View original paper by Stewart.
format article
author Kidess A
El Salloukh A
Dutt P
Keane PA
Tsaloumas MD
Denniston AK
author_facet Kidess A
El Salloukh A
Dutt P
Keane PA
Tsaloumas MD
Denniston AK
author_sort Kidess A
title Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
title_short Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
title_full Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
title_fullStr Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
title_full_unstemmed Measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
title_sort measurement bias between optical coherence tomography instruments can affect access to treatment: a new lottery
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/9d19d9365766444e991a96d5029225b2
work_keys_str_mv AT kidessa measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
AT elsalloukha measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
AT duttp measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
AT keanepa measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
AT tsaloumasmd measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
AT dennistonak measurementbiasbetweenopticalcoherencetomographyinstrumentscanaffectaccesstotreatmentanewlottery
_version_ 1718403090782093312

Ejemplares similares